Nebivolol — $0 on Listed Strengths

Other medications in Heart & Cardiovascular

• Nesiritide
• Nicardipine
• Nifedipine
• Nisoldipine
• Nitroprusside
• Olmesartan
• Perindopril
• Pindolol

About Nebivolol

Nebivolol is a distinctive beta-blocker frequently prescribed for the effective management of high blood pressure. If you're seeking a powerful yet gentle way to control your hypertension, nebivolol could be a beneficial option. The best part? Living with high blood pressure, or hypertension, significantly increases your risk for serious health issues like heart attack and stroke. That's why finding the right medication to manage it is so important. Nebivolol is one such medication, often chosen for its unique profile in treating this common condition. ### What Nebivolol Treats

Nebivolol is primarily prescribed to treat essential hypertension, meaning high blood pressure that isn't caused by another underlying condition. By effectively lowering blood pressure, nebivolol helps reduce the strain on your heart and blood vessels, thereby decreasing your overall cardiovascular risk. It's an important tool in a comprehensive treatment plan aimed at maintaining long-term heart health. ### How Nebivolol Works

Unlike some older beta-blockers, nebivolol stands out with a dual mechanism of action. Firstly, it's a highly selective beta-1 adrenergic receptor blocker. This means it primarily targets the beta-1 receptors in your heart, slowing your heart rate and reducing the force with which your heart pumps blood. This lessens the workload on your heart. Secondly, and uniquely, nebivolol also helps widen your blood vessels (vasodilation) by increasing the production of nitric oxide, a natural substance in your body that relaxes blood vessel walls. This combination of reduced heart activity and relaxed blood vessels leads to a more effective and often better-tolerated reduction in blood pressure compared to some other medications in its class. ### Typical Costs of Nebivolol

Managing a chronic condition like hypertension often means ongoing medication costs, which can quickly add up. The price of nebivolol can vary significantly depending on whether you're prescribed the brand-name version or a generic, your dosage, and your pharmacy. Without insurance or discount programs, a monthly supply can range from tens to hundreds of dollars, potentially creating a financial burden for many individuals and families. These costs can be a barrier to consistent adherence, which is vital for effective blood pressure control. That's why we're proud to offer our members an unparalleled benefit for essential medications like nebivolol. For covered formulations of nebivolol, TheDrugClub

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Nebivolol is approved for (FDA label)

Nebivolol is a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) 1.1 Hypertension Nebivolol tablets are indicated for the treatment of hypertension, to lower blood pressure [see Clinical Studies ( 14.1 )]. Nebivolol tablets may be used alone or in combination with other antihypertensive agents [see Drug Interactions ( 7 )]. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs.

Source: Read the full FDA label on DailyMed. Label effective date: June 9, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Nebivolol (FDA label)

Nebivolol tablets are available for oral administration containing nebivolol hydrochloride equivalent to 2.5 mg, 5 mg, 10 mg, and 20 mg of nebivolol. Nebivolol tablets are triangular-shaped, biconvex, unscored, differentiated by color and are debossed with “ S ” on one side and the number (671, 672, 673, or 674) on the other side. Tablets: 2.5, 5, 10, 20 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 3e9e1048-b5ea-4d6a-9363-3ee0d059e088. SPL document ID: 65277848-9bcf-4791-9184-ae0080f1871d. Label effective date: June 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Nebivolol (FDA label)

Most common adverse reactions ( 6.1 ): • Headache, fatigue To report SUSPECTED ADVERSE REACTIONS, contact Solco Healthcare US, LLC at 1-866-257-2597 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Studies Experience Nebivolol tablets have been evaluated for safety in patients with hypertension and in patients with heart failure. The observed adverse reaction profile was consistent with the pharmacology of the drug and the health status of the patients in the clinical trials. Adverse reactions reported for each of these patient populations are provided below.

Source: FDA prescribing information (DailyMed). Set ID: 3e9e1048-b5ea-4d6a-9363-3ee0d059e088. SPL document ID: 65277848-9bcf-4791-9184-ae0080f1871d. Label effective date: June 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Nebivolol (FDA label)

Nebivolol tablets are contraindicated in the following conditions: • Severe bradycardia • Heart block greater than first degree • Patients with cardiogenic shock • Decompensated cardiac failure • Sick sinus syndrome (unless a permanent pacemaker is in place) • Patients with severe hepatic impairment (Child-Pugh >B) • Patients who are hypersensitive to any component of this product. • Severe bradycardia ( 4 ) • Heart block greater than first degree ( 4 ) • Patients with cardiogenic shock ( 4 ) • Decompensated cardiac failure ( 4 ) • Sick sinus syndrome (unless a permanent pacemaker is in place) ( 4 ) • Patients with severe hepatic impairment (Child-Pugh >B) ( 4 ) • Hypersensitive to any component of this product ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 3e9e1048-b5ea-4d6a-9363-3ee0d059e088. SPL document ID: 65277848-9bcf-4791-9184-ae0080f1871d. Label effective date: June 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Nebivolol (FDA label)

• Acute exacerbation of coronary artery disease upon cessation of therapy: Do not abruptly discontinue. ( 5.1 ) • Diabetes: May mask symptoms of hypoglycemia and alter glucose levels; monitor ( 5.5 ) 5.1 Abrupt Cessation of Therapy Do not abruptly discontinue nebivolol tablets therapy in patients with coronary artery disease. Severe exacerbation of angina, myocardial infarction and ventricular arrhythmias have been reported in patients with coronary artery disease following the abrupt discontinuation of therapy with β-blockers. Myocardial infarction and ventricular arrhythmias may occur with or without preceding exacerbation of the angina pectoris. Caution patients without overt coronary artery disease against interruption or abrupt discontinuation of therapy. As with other β-blockers, when discontinuation of nebivolol tablets is planned, carefully observe and advise patients to minimize physical activity. Taper nebivolol tablets over 1 to 2 weeks when possible.

Source: FDA prescribing information (DailyMed). Set ID: 3e9e1048-b5ea-4d6a-9363-3ee0d059e088. SPL document ID: 65277848-9bcf-4791-9184-ae0080f1871d. Label effective date: June 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Nebivolol (FDA label)

• CYP2D6 enzyme inhibitors may increase nebivolol levels. ( 7.1 ) • Reserpine or clonidine may produce excessive reduction of sympathetic activity. ( 7.2 ) • Both digitalis glycosides and β-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia. ( 7.3 ) • Verapamil- or diltiazem-type calcium channel blockers may cause excessive reductions in heart rate, blood pressure, and cardiac contractility. ( 7.4 ) 7.1 CYP2D6 Inhibitors Use caution when nebivolol tablets are co-administered with CYP2D6 inhibitors (quinidine, propafenone, fluoxetine, paroxetine, etc.) [see Clinical Pharmacology ( 12.5 )] . 7.2 Hypotensive Agents Do not use nebivolol tablets with other β-blockers. Closely monitor patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, because the added β-blocking action of nebivolol tablets may produce excessive reduction of sympathetic activity.

Source: FDA prescribing information (DailyMed). Set ID: 3e9e1048-b5ea-4d6a-9363-3ee0d059e088. SPL document ID: 65277848-9bcf-4791-9184-ae0080f1871d. Label effective date: June 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.